Testicular cancer update

Nabil Adra, Lawrence Einhorn

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The advances seen in the treatment of testicular cancer are among the great achievements in modern medicine. These advances were made possible by the collaborative efforts of cancer researchers around the world. Investigators have been able to address many questions regarding the treatment of patients with disease limited to the testis, those with metastasis to the retroperitoneum only, and those with advanced metastatic disease. Questions answered include the chemotherapeutic agents to be used and in what combinations, the proper intensity of treatment and appropriate dosing, the optimal number of cycles of chemotherapy according to validated risk stratification, appropriate surgical approaches that preserve sexual function, the treatment of relapsed disease, what supportive care measures to take, and survivorship issues following treatment of testicular cancer. Today, cure is achievable in 95% of all patients with testicular cancer and 80% of those who have metastatic disease. Despite remarkable results with frontline and salvage combination chemotherapy, metastatic testicular cancer remains incurable in approximately 10% of patients, and novel treatment approaches are warranted. This review highlights past and recent discoveries in the treatment of patients with testicular cancer.

Original languageEnglish (US)
Pages (from-to)386-396
Number of pages11
JournalClinical Advances in Hematology and Oncology
Volume15
Issue number5
StatePublished - May 1 2017

Fingerprint

Testicular Neoplasms
Therapeutics
Research Personnel
Modern 1601-history
Combination Drug Therapy
Testis
Survival Rate
Neoplasm Metastasis
Drug Therapy
Neoplasms

Keywords

  • Germ cell tumor
  • Survival
  • Testicular cancer
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Testicular cancer update. / Adra, Nabil; Einhorn, Lawrence.

In: Clinical Advances in Hematology and Oncology, Vol. 15, No. 5, 01.05.2017, p. 386-396.

Research output: Contribution to journalArticle

@article{7d3dc00c03c84e958324373f99fa6b7b,
title = "Testicular cancer update",
abstract = "The advances seen in the treatment of testicular cancer are among the great achievements in modern medicine. These advances were made possible by the collaborative efforts of cancer researchers around the world. Investigators have been able to address many questions regarding the treatment of patients with disease limited to the testis, those with metastasis to the retroperitoneum only, and those with advanced metastatic disease. Questions answered include the chemotherapeutic agents to be used and in what combinations, the proper intensity of treatment and appropriate dosing, the optimal number of cycles of chemotherapy according to validated risk stratification, appropriate surgical approaches that preserve sexual function, the treatment of relapsed disease, what supportive care measures to take, and survivorship issues following treatment of testicular cancer. Today, cure is achievable in 95{\%} of all patients with testicular cancer and 80{\%} of those who have metastatic disease. Despite remarkable results with frontline and salvage combination chemotherapy, metastatic testicular cancer remains incurable in approximately 10{\%} of patients, and novel treatment approaches are warranted. This review highlights past and recent discoveries in the treatment of patients with testicular cancer.",
keywords = "Germ cell tumor, Survival, Testicular cancer, Treatment",
author = "Nabil Adra and Lawrence Einhorn",
year = "2017",
month = "5",
day = "1",
language = "English (US)",
volume = "15",
pages = "386--396",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "5",

}

TY - JOUR

T1 - Testicular cancer update

AU - Adra, Nabil

AU - Einhorn, Lawrence

PY - 2017/5/1

Y1 - 2017/5/1

N2 - The advances seen in the treatment of testicular cancer are among the great achievements in modern medicine. These advances were made possible by the collaborative efforts of cancer researchers around the world. Investigators have been able to address many questions regarding the treatment of patients with disease limited to the testis, those with metastasis to the retroperitoneum only, and those with advanced metastatic disease. Questions answered include the chemotherapeutic agents to be used and in what combinations, the proper intensity of treatment and appropriate dosing, the optimal number of cycles of chemotherapy according to validated risk stratification, appropriate surgical approaches that preserve sexual function, the treatment of relapsed disease, what supportive care measures to take, and survivorship issues following treatment of testicular cancer. Today, cure is achievable in 95% of all patients with testicular cancer and 80% of those who have metastatic disease. Despite remarkable results with frontline and salvage combination chemotherapy, metastatic testicular cancer remains incurable in approximately 10% of patients, and novel treatment approaches are warranted. This review highlights past and recent discoveries in the treatment of patients with testicular cancer.

AB - The advances seen in the treatment of testicular cancer are among the great achievements in modern medicine. These advances were made possible by the collaborative efforts of cancer researchers around the world. Investigators have been able to address many questions regarding the treatment of patients with disease limited to the testis, those with metastasis to the retroperitoneum only, and those with advanced metastatic disease. Questions answered include the chemotherapeutic agents to be used and in what combinations, the proper intensity of treatment and appropriate dosing, the optimal number of cycles of chemotherapy according to validated risk stratification, appropriate surgical approaches that preserve sexual function, the treatment of relapsed disease, what supportive care measures to take, and survivorship issues following treatment of testicular cancer. Today, cure is achievable in 95% of all patients with testicular cancer and 80% of those who have metastatic disease. Despite remarkable results with frontline and salvage combination chemotherapy, metastatic testicular cancer remains incurable in approximately 10% of patients, and novel treatment approaches are warranted. This review highlights past and recent discoveries in the treatment of patients with testicular cancer.

KW - Germ cell tumor

KW - Survival

KW - Testicular cancer

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85020810750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020810750&partnerID=8YFLogxK

M3 - Article

C2 - 28591093

AN - SCOPUS:85020810750

VL - 15

SP - 386

EP - 396

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 5

ER -